Fig. 5: Intratumoral mtDSN treatment induces abscopal effects with tumor-specific immunity.
From: Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity
a Schedule of the bilateral 4T1 tumor model for assessing the immune abscopal effect triggered by mtDSN-2 vaccination. i.t., intratumoral. Growth profiles of primary (b) and distant (c) tumors (n = 8 mice/group). d Kaplan–Meier survival of 4T1 tumor-bearing BALB/c mice (n = 8 mice/group). e Immunofluorescence staining of the tumor sections showed CD8+ T-cell infiltration. n = 3 mice/group. f Mouse body weights after each treatment (n = 8 mice/group). g Schedule of bilateral heterologous tumor inoculation in BALB/c mice and treatment. Growth profiles of primary 4T1 tumors (h) and distant CT26 tumors (i) (n = 10 mice/group). j Schedule of tumor antigen-specific T-cell activation analysis in mice with B16F10-OVA tumor. k H-2Kb-restricted OVA257-264-specific CD8+ T cells in tumors, as determined by flow cytometry analysis (n = 6 mice/group). l–o Flow cytometry analysis and corresponding quantification of activated H-2Kb-restricted OVA257-264-specific CD8+ T cells in tumor (l, m) and spleen (n, o) tissues (n = 6 mice/group). The data are presented as the mean ± s.d. Statistical analysis by two-way ANOVA with Sidak’s multiple comparisons test (b, c, h), log-rank test (d), or Student’s t test (k, m, o). Source data are provided as a Source data file.
